All In Biotech

BLA 761244 · Boehringer Ingelheim Pharmaceuticals INC

Spevigo

Spesolimab-Sbzo · Intravenous · Interleukin-36 Receptor Antagonist

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Sep 1, 2022: To treat generalized pustular psoriasis flares

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 1, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

33

7 Phase 3, 1 recruiting

FAERS reports

403

213 serious, 28 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 8, 2026.

SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. SPEVIGO is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. ( 1 )

Mechanism: Spesolimab-sbzo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specifically binding to the IL36R. Binding of spesolimab-sbzo to IL36R prevents the subsequent activation of IL36R by its ligands (IL-36 α, β and γ) and downstream activation of pro-inflammatory and pro-fibrotic pathways. The precise mechanism linking reduced IL36R activity and the treatment of flares of GPP is unclear.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 2025 Supplement 4 · Efficacy OrphanLetter
  • Mar 18, 2024 Supplement 3 · Efficacy Breakthrough therapyOrphanLabelLetter
  • Sep 1, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
  • SPEVIGO · SPESOLIMAB-SBZO 900MG · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Spesolimab" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • generalised pustular psoriasis82
  • drug ineffective54
  • off label use26
  • pruritus22
  • rash20
  • fatigue19
  • pustular psoriasis19
  • psoriasis16
  • pustule15
  • maternal exposure during pregnancy14
  • asthenia13
  • pyrexia13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202213
202364
202498
2025115
2026113

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Spevigo* (Spesolimab-Sbzo)

2024 spending

$4.9M

Beneficiaries

55

185 claims

Per beneficiary

$89,061

$7,736.84 per unit

View as table
YearSpending
2020$0
2021$0
2022$583,545
2023$1,705,416
2024$4,898,328

Part B: Spevigo (Spesolimab-Sbzo) · HCPCS J1747

2024 spending

$4.6M

Beneficiaries

47

96 claims

Per beneficiary

$98,343

2024 ASP limit $60.80 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,732,343
2024$4,622,120

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.